Sartorius Opens New Application Center in Shanghai
![](/46/pdcnewsitem/03/38/47/4hwpUB6vFwE3Zkm.jpg)
Sartorius has officially opened a new application center at its Shanghai office. Among the guests, representatives from the Shanghai government, customers from the biopharmaceutical industry, as well as business partners and the media, attended the opening ceremony.
With a floor space of 240 square meters, or 2600 square feet, the new application center offers ample room for product demonstrations, trial runs and training sessions. At this center, customers from the biopharmaceutical industry can now test the latest Sartorius products for cell cultivation, media and buffer preparation, sterile filtration, cross-flow purification, membrane chromatography, virus clearance and aseptic processing. For laboratory customers, Sartorius showcases its entire range of lab instruments and consumables from balances, moisture analysers, pipettes and water purification systems to filters and products for microbiological testing and quality control.
In his speech, Michael Melingo, member of the Sartorius Group Executive Committee and in charge of marketing, sales and services of Sartorius’ lab business, underlined the importance of Shanghai as a strategic and geographical hub for Sartorius in Asia. “Located close to our customers’ R&D centers in Shanghai and other biotech hotspots like Seoul, Tokyo and Singapore, our application center is the place to be for top scientists to talk about the latest industrial and technological trends.” With the substantial investment in this new application center, Sartorius has further extended its footprint in Asia.
Dr Jörg Lindenblatt, the Senior Vice President of Sales Asia/Pacific for Bioprocess Solutions, emphasised the practical approach of the application center. “Our application center is not just a showroom for our extensive range of lab and bioprocess products. We invite our customers to gain hands-on experience with our
technologies during training and demonstration. By doing this, we can demonstrate the benefits of the high degree of seamless integration of the newest state-of-the-art technology for biotech manufacturing.” Besides being used for demonstration purposes, the new application center will serve as training facility for customers,
distributors and staff.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance